The Lancet Oncology最新文献

{"title":"Synthetic progestin use and young-onset breast cancer","authors":"Stephen Nigel Birrell","doi":"10.1016/s1470-2045(25)00425-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00425-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revisiting prostate cancer active surveillance candidacy","authors":"Daniel E Spratt, Edward M Schaeffer","doi":"10.1016/s1470-2045(25)00438-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00438-3","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"100 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BrECADD and fertility: an ongoing concern – Authors' reply","authors":"Justin Ferdinandus, Janina Jablonski, Peter Borchmann, Karolin Behringer","doi":"10.1016/s1470-2045(25)00529-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00529-7","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"69 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sharing experiences and forming bonds at the Edinburgh Fringe","authors":"Peter Ranscombe","doi":"10.1016/s1470-2045(25)00555-8","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00555-8","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toxicity assessment bias in the PACE-C trial","authors":"Lanwei Guo","doi":"10.1016/s1470-2045(25)00436-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00436-x","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health-care transitions for young people living beyond childhood and adolescent cancer: recommendations from the EU–CAYAS–NET consortium","authors":"Jikke Wams, Elvira C van Dalen, Jaap G den Hartogh, Maria Otth, Tiago Costa, Jan Willem Gorter, Alied M van der Aa-van Delden, Anna Panasiuk, Bernhard Wörmann, Claire Berger, Edit Bardi, Elna Hamilton Larsen, Emma Potter, Esther Lasheras Soria, Gill Levitt, Gisela Michel, Helena J H van der Pal, Jelena Roganovic, Judith de Bont, Lieselotte Wauters, Kylie B O'Brien","doi":"10.1016/s1470-2045(25)00410-3","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00410-3","url":null,"abstract":"Childhood and adolescent cancer survivors (age at diagnosis: 0–21 years) face increased risk for long-term health complications and less favourable outcomes in terms of functioning and social participation. Moreover, they often experience inadequate health-care transitions to appropriate services after leaving paediatric or adolescent services, while the prevalence and severity of late effects increase as they become adults. To address transition challenges, we developed evidence-based recommendations as part of the European Network of Youth Cancer Survivors project with the goal to improve health-care transitions to both long-term survivorship and adult care, ensuring continuity and addressing survivors’ unique needs. Using evidence-based methods, an international and multidisciplinary guideline panel developed a clinical practice guideline for health-care transitions. Patient representatives were included at all steps of the development process. The guideline panel systematically reviewed data from PubMed from Jan 1, 1990, to April 8, 2025, and graded the evidence with the GRADE methodology. In addition, existing guidelines and perspectives from patients, parents, and health-care providers were considered when formulating recommendations. Of 2538 citations identified, 86 articles met the inclusion criteria, focusing on health-care transitions for cancer survivors up to age 21 years at diagnosis or for patients with chronic conditions (eg, diabetes and asthma) to extrapolate insights from these populations. The quality of evidence varied from very low to moderate. Unique needs and preferences were captured, ensuring a comprehensive and patient-centred approach to the recommendations. In total, 44 strong recommendations were formulated for health-care transitions of childhood and adolescent cancer survivors. We integrated existing evidence and multistakeholder expertise and developed actionable recommendations that support smooth transitions for childhood and adolescent cancer survivors and improve their lives as adults. Implementing this guideline will enhance the quality of care and improve quality of life by addressing the specific health-care transition needs of this vulnerable population.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study","authors":"Mingzhao Xing, Shuhuang Lin, Aarti Mathur, Ying Li, Bela Bendlova, Vlasta Kuklikova, Miguel Melo, Tito Teles Jesus, Paula Soares, Carla Colombo, Laura Fugazzola, Norisato Mitsutake, Michiko Matsuse, Ayaka Sako, Ana Patricia Estrada-Florez, Luis G Carvajal-Carmona, Mabel E Bohórquez, Caterina Mian, Federica Vianello, Christine J O'Neill, Young Joo Park","doi":"10.1016/s1470-2045(25)00399-7","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00399-7","url":null,"abstract":"<h3>Background</h3>The four-stage American Joint Committee on Cancer (AJCC) staging system has been used for almost 50 years for assessing the risk of multiple cancers; the AJCC classification for papillary thyroid cancer is solely based on clinical parameters, and despite updated editions its accuracy remains suboptimal. We aimed to evaluate whether the performance of the AJCC system could be improved by integrating tumour genetic statuses of <em>BRAF</em> and <em>TERT</em> genes.<h3>Methods</h3>This retrospective multicentre cohort study used patient medical records from 15 medical centres across ten countries for patients (of all ages) with papillary thyroid cancer who had been surgically treated with total thyroidectomy or hemithyroidectomy with or without neck dissection, followed by postoperative radioiodine ablation and appropriate thyroid-stimulating hormone level targeting. Testing for <em>BRAF</em><sup>V600E</sup> and <em>TERT</em> promotor (<em>TERT</em>p) mutations was performed on genomic DNA isolated from surgical or cytological specimens of primary papillary thyroid cancer tumours at each centre. Data from all medical centres were pooled for aggregated analyses of the relationship between the genetic status and papillary thyroid cancer-specific mortality for each of the four classical stages of the 7th and 8th editions of the AJCC system (AJCC7E and AJCC8E). The primary endpoint was papillary thyroid cancer-specific mortality, characterised by mortality rates per 1000 person-years.<h3>Findings</h3>Using patients who were treated for papillary thyroid cancer between January 1979, to July 2023 at the 15 centres, our cohort comprised of 4746 patients (3612 [76·1%] females and 1134 [23·9%] males), with median age of 48 years (IQR 37–59; 89 [1·9%] patients aged ≤18 years). For the 4400 patients with available ethnicity data, the majority were Asian (2140 [48·6%]) and 2096 (47·6%) were White. For AJCC7E, compared with the original stages, the genetic duet of <em>BRAF</em><sup>V600E</sup> and <em>TERT</em>p mutations was associated with increased mortality in all stages versus the corresponding original stages, although the HR for stage I did not reach statistical significance. Those with wildtype <em>BRAF</em><sup>V600E</sup> and <em>TERT</em>p had flat survival curves for stages I–III with AJCC7E and stages I–II of AJCC8E. Patients with dual mutations had reductions in survival across all stages for the AJCC7E (stage I HR 5·96 [95% CI 0·73–48·66]; p=0·10; stage II 5·94 [95% CI 1·42–24·91]; p=0·015; stage III 4·04 [95% CI 1·87–8·70]; p=0·00037; and stage IV 1·79 [95% CI 1·15–2·76]; p=0·0092). <em>TERT</em>p mutation alone was also significantly associated with a significant increase in mortality for stage IV (3·57 [2·01–6·37]; p<0·0001). For AJCC8E, we observed a similar pattern of increased mortality when both mutations were present compared to mortality in the original staging, with significant differences in HR for stages I and II ","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium","authors":"James P Blackmur, J C Koen van der Mijn, Anne Y Warren, Lisa Browning, Femke Burgers, Michelle S Hirsch, Payal Kapur, Rohit Mehra, Priya Rao, Sabina Signoretti, Axel Bex, Grant D Stewart, Maurits L van Montfoort, James O Jones","doi":"10.1016/s1470-2045(25)00345-6","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00345-6","url":null,"abstract":"Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological response reporting in renal cell carcinoma and develop a recommendation on tissue preparation and response reporting for neoadjuvant treatment. We conducted a systematic review of publications on the PubMed and Web of Science databases to identify manuscripts reporting response to pre-surgical therapy in renal cell carcinoma. 119 eligible papers were identified. Only five (4%) studies included details of how pathological response had been assessed. Qualitative statements on residual tumour were common (55 [46%] studies), but only eight (7%) studies used a quantitative assessment of pathological response. Guidelines for tissue preparation and pathological response reporting were reviewed at an international workshop held at the Netherlands Cancer Institute in October, 2024, and further developed through expert discussions. To assess neoadjuvant pathological response, nephrectomy specimens should be sampled with the use of a standardised baseline approach with consideration for more extensive sampling. Microscopic assessment should quantify the residual viable tumour in 10% intervals and greatest linear extent. Clinical details, including the neoadjuvant therapy received, should accompany the pathological assessment. In this systematic review, we describe a standardised method for assessment and reporting pathological response, initially intended for use in clinical trials or research settings. These guidelines will help investigators to assess whether the degree of pathological response is linked to survival outcomes and will inform future standard reporting practices.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenges for Chinese innovative cancer drugs in going global: insights from multiregional clinical trials","authors":"Xin Du, Zhong Zhao, Xiaoqian Sun, Yongbing Zhang, Yi Zhang, Xingxian Luo","doi":"10.1016/s1470-2045(25)00350-x","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00350-x","url":null,"abstract":"Since the reform of China's drug review and approval in 2015, it has successfully stimulated the enthusiasm of domestic pharmaceutical companies to carry out innovative drug research and development, especially in oncology. Chinese pharmaceutical companies that developed cancer drugs have begun shifting from an in China, for China model to an in China, for global model given the constrained market share. However, many challenges are confronting Chinese pharmaceutical companies when entering overseas markets. Conducting multiregional clinical trials (MRCTs) has been widely regarded by the industry as a crucial step for innovative drugs to achieve overseas commercialisation. The number of MRCTs conducted by Chinese pharmaceutical companies in the cancer field has substantially increased, but it remains scarce compared with multinational pharmaceutical companies. The populations enrolled in these trials conducted by Chinese pharmaceutical companies were most frequently from China, followed by the USA and Australia. The success rate of MRCTs conducted for cancer drugs was substantially lower in the USA than in China. As of May 25, 2025, Chinese pharmaceutical companies obtained approval from the US Food and Drug Administration and European Medicines Agency for 14 cancer indications each. Most of the pivotal trials supporting the US Food and Drug Administration and European Medicines Agency approval of these cancer drugs were conducted as MRCTs. The main challenges for these cancer drugs when listed overseas include little diversity in clinical trial populations and manufacturing issues. Geopolitical shifts have accelerated Chinese pharmaceutical companies to expansion into so-called Belt and Road markets (eg, southeast Asia and Africa). China should actively support the implementation of MRCTs, enhance the diversity of trial populations, and deepen collaboration with international regulatory agencies to accelerate the global commercialisation of domestic novel cancer drugs.","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AJCC9V classification for HPV-positive oropharyngeal carcinoma","authors":"Shaokun Liu, Boxuan Han, Shiqian Liu","doi":"10.1016/s1470-2045(25)00473-5","DOIUrl":"https://doi.org/10.1016/s1470-2045(25)00473-5","url":null,"abstract":"No Abstract","PeriodicalId":22865,"journal":{"name":"The Lancet Oncology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145189193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}